

Aubagne, France | February 16, 2026

Sartorius Stedim Biotech releases Universal Registration Document 2025

Sartorius Stedim Biotech, a leading partner of the biopharma industry, today released its Universal Registration Document 2025 including the Annual Financial Report. The document is available at the following link: <https://www.sartorius.com/urd2025>

Financial calendar

March 24, 2026	Annual Shareholders' Meeting
April 23, 2026	Publication of the first quarter results for January to March 2026
July 23, 2026	Publication of half-year results for January to June 2026
October 22, 2026	Publication of nine-month results January to September 2026

A profile of Sartorius Stedim Biotech

Sartorius Stedim Biotech is a leading international partner of the biopharmaceutical industry. As a provider of innovative solutions, the company based in Aubagne, France, helps its customers to manufacture biotech medications, such as cell and gene therapies, safely, rapidly, and sustainably. The shares of Sartorius Stedim Biotech S.A. are quoted on the Euronext Paris. The company has a strong global reach with manufacturing and R&D sites as well as sales entities in Europe, North America, and Asia. Sartorius Stedim Biotech regularly expands its portfolio through acquisitions of complementary technologies. In 2025, the company generated sales revenue of around 3 billion euros, according to preliminary figures. Currently, more than 10,200 employees are working for customers around the globe.

Visit our [newsroom](#) and follow us on [LinkedIn](#).

Contact

Verena Sattel
External Communications
+49 551 308 9261
verena.sattel@sartorius.com